As Bird Flu Outbreak Worsens, Zoetis Gets Green Light for Poultry Vaccine
TUESDAY, Feb. 18, 2025 (HealthDay News) -- The U.S. Department of Agriculture (USDA) has granted conditional approval for a new bird flu vaccine for poultry. This new avian flu vaccine, developed by New Jersey-based Zoetis, was approved last week after meeting safety and efficacy standards.
BTIG lowered the firm’s price target on Zoetis (ZTS) to $200 from $225 and keeps a Buy rating on the shares. The company delivered an in-line ...
Zoetis received a USDA conditional license for its H5N2 avian flu vaccine for chickens, marking a step in addressing the ...
Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance. Click here to find ...
In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on Zoetis (ZTS – Research Report). The ...
Zoetis slightly topped analyst estimates for profitability and met those for revenue in its fourth quarter. But as investors ...
Investment analysts at William Blair reduced their Q1 2025 EPS estimates for shares of Zoetis in a note issued to investors ...
Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...
Zoetis exceeded market expectations in Q4 2024, with impressive financial performance despite challenges in specific segments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback